Brito-Orama Sebastian, Sheth Rahul A
Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Immunother Precis Oncol. 2023 Jan 17;6(2):84-90. doi: 10.36401/JIPO-22-8. eCollection 2023 May.
Systemically administered immunotherapies have revolutionized the care of patients with cancer; however, for many cancer types, most patients do not exhibit objective responses. Intratumoral immunotherapy is a burgeoning strategy that is designed to boost the effectiveness of cancer immunotherapies across the spectrum of malignancies. By locally administering immune-activating therapies into the tumor itself, immunosuppressive barriers in the tumor microenvironment can be broken. Moreover, therapies too potent for systemic delivery can be safely administered to target location to maximize efficacy and minimize toxicity. In order for these therapies to be effective, though, they must be effectively delivered into the target tumor lesion. In this review, we summarize the current landscape of intratumoral immunotherapies and highlight key concepts that influence intratumoral delivery, and by extension, efficacy. We also provide an overview of the breadth and depth of approved minimally invasive delivery devices that can be considered to improve delivery of intratumoral therapies.
全身给药的免疫疗法彻底改变了癌症患者的治疗方式；然而，对于许多癌症类型，大多数患者并未表现出客观反应。瘤内免疫疗法是一种新兴策略，旨在提高各种恶性肿瘤的癌症免疫疗法的有效性。通过将免疫激活疗法局部施用于肿瘤本身，可以打破肿瘤微环境中的免疫抑制屏障。此外，对于全身给药来说过于强效的疗法可以安全地施用于靶部位，以最大限度地提高疗效并最小化毒性。然而，为了使这些疗法有效，它们必须有效地递送至靶肿瘤病灶。在本综述中，我们总结了瘤内免疫疗法的当前现状，并强调了影响瘤内递送进而影响疗效的关键概念。我们还概述了可用于改善瘤内疗法递送的已批准的微创递送装置的广度和深度。
